Saturday, August 28, 2021 1:00:41 AM
The company hired Aamir Malik from McKinsey & Company as its chief business innovation officer. He’ll succeed John Young, who's retiring in early 2022 after a 34-year career at Pfizer, as the drugmaker unveiled in July.
Malik’s new role, beginning Aug. 30, spans business development, portfolio management, pipeline prioritization and new business ventures plus innovative access programs with payers and governments.
Young is walking away with glorious dealmaking achievements after just a little less than three years in the job. Perhaps none is more important than the mRNA COVID-19 vaccine collaboration with BioNTech, which gives Pfizer a product with expected 2021 sales of $33.5 billion, according to its tally of supply contracts signed as of mid-July.
The COVID shot, branded as Comirnaty, has just become the first pandemic vaccine to graduate from an emergency use authorization to win a full FDA approval. Armed with positive antibody response data from a phase 3 trial, Pfizer and BioNTech said Wednesday that they have launched a rolling submission seeking the FDA's blessing for a booster shot.
Comirnaty's success infuses Pfizer with a lot of cash to do more deals. But as CEO Albert Bourla, Ph.D., has repeatedly emphasized, revenues from the vaccine don’t necessarily affect Pfizer’s strategic direction—and might not even help it pull off more M&A deals.
“Our strategy on capital allocation was not driven with how much capital we have; was driven with how much opportunity we have,” Bourla said during a conference call in May.
The chief executive has said that Pfizer is doing deals to shore up growth in the second part of the decade. Investors should expect to see many transactions around phase 2 and phase 3 assets, he added.
Besides Comirnaty, Young was credited with Pfizer’s acquisition of antibiotics maker Arixa in 2020. Last year, he also struck up partnerships with Myovant Sciences on newly FDA-approved cancer drug Orgovyx, with CStone Pharmaceuticals on PD-L1 drug sugemalimab in China and with Valneva for rights to a Lyme disease vaccine candidate. Before that, he helped orchestrated the $11.4 billion buyout of cancer specialist Array BioPharma in 2019.
Young also oversaw the closing of two large-scale spinoffs that left Pfizer with a sole focus on innovative drugs.
Pfizer in 2019 wrapped up its consumer health merger with GlaxoSmithKline’s counterpart portfolio. GSK is now preparing to spin off that joint venture into a standalone company next year. In 2020, Pfizer shed its Upjohn established medicines franchise, which Young previously led, in a deal with Mylan to form Viatris.
And just this week, in what will likely be the last deal done with Young in the dealmaker seat, was Pfizer's buyout of immuno-oncology biotech Trillium for $2.3 billion to bolster its cancer pipeline. Not a bad way to bow out.
In his chief business officer role, Young—and soon Malik—also leads a management committee that takes care of setting R&D priorities and strategies. Last year, the team’s work led to seven positive proof-of-concept readouts, endorsement of five pivotal study starts and prioritization of investments in six pivotal programs, according to a securities filing in March.
In addition, market access also falls within the title’s purview, including ensuring all Pfizer phase 3 programs have value-based access solutions incorporated into their plans.
All those jobs will soon go to Malik, who’s currently McKinsey’s managing partner for U.S. operations. As Bourla noted in a Friday statement, Malik joins with 25 years of experience “developing innovative growth strategies, guiding mergers and acquisitions, and implementing high-impact programs” for life sciences companies.
Before his current role, Malik led the consulting firm’s global pharmaceuticals and medical products practice. He has advised “several of the most significant healthcare mergers and acquisitions of the past two decades,” according to McKinsey.
https://www.fiercepharma.com/pharma/pfizer-taps-mckinsey-veteran-malik-to-succeed-biontech-covid-19-vaccine-dealmaker-young-as
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM